Skip to content

A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer

A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness of Sublobar Dissection in the Chinese Patients With Non-small Cell Lung Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03427567
Enrollment
3902
Registered
2018-02-09
Start date
2017-12-01
Completion date
2018-03-30
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

Chinese, real-world evidences, NSCLC, sublobar dissection

Brief summary

A study to evaluate effectiveness of sublobar dissection in patients with non-small cell lung cancer

Detailed description

This is a multi-centre real-world non-interventional observational study. The study data on patient demographic/tumor biological characteristics and clinical treatments were retrospectively collected to evaluate effectiveness of sublobar dissection in the Chinese patients with non-small cell lung cancer who received sublobar dissection.

Interventions

PROCEDURESublobar dissection

Sublobar dissection plus lymphadenectomy

Sponsors

LinkDoc Technology (Beijing) Co. Ltd.
CollaboratorINDUSTRY
Tongji Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \>= 18 years old; * Patients who received sublobar dissection from 2014 to 2017 (segment dissection/wedge dissection/segment and wedge dissections); * Patients who received selective or systematic lymphadenectomy; * Pathologically diagnosed patients with non-small cell lung cancer; * Pathological staging: I, II

Exclusion criteria

* Patients who received cancer treatments before surgeries (adjuvant therapies including chemotherapies, radiotherapies, target therapies); * Patients who received late-phase or intolerant palliative lobectomy or compromise sublobar dissection;

Design outcomes

Primary

MeasureTime frameDescription
Overall survival2014 - 2017Overall survival

Secondary

MeasureTime frameDescription
Overall survivals in subgroups2014 - 2017Overall survivals categorised by tumor biological characteristics

Other

MeasureTime frameDescription
Impact factors of overall survival2014 - 2017Impact factors of overall survival as measured by patient demographic/tumor biological characteristics and clinical treatments
Death rates after surgeries2014 - 2017Death rates after surgeries
Impact factors of death rates after surgeries2014 - 2017Impact factors of death rates after surgeries
Incidence of complications after surgeries2014 - 2017Incidence of complications after surgeries

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026